

## Key Findings

**The global autoimmune market generated sales of \$31.9bn in 2007**, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of \$51.0bn in 2013.


**Immunosuppressant drugs dominate the autoimmune market**, with four products from this class accounting for 40.3% of total market sales. The highest selling immunosuppressant drug was J&J/Schering-Plough's Remicade, with 42.1% of total sales in this class.

**Pfizer's Celebrex dominated the COX-II market with a share of 81.3% in 2007**. Celebrex maintained blockbuster status despite the earlier withdrawals of major blockbuster COX-II inhibitors such as Vioxx and Bextra.

**Roche's Actemra is expected to be launched in the US during Q1 2010**, in view of the FDA's request for additional data and Roche's risk mitigation strategy. Actemra is forecast to generate sales of \$680m in 2013.

**Amgen is the global autoimmune market leader**, having accrued a market share of 11.2% (\$3.6bn) in 2007. This was driven almost entirely by Enbrel (\$3.5bn) which had a sales increase of 12.2%.

**Novartis' developmental MS drug 'fingolimod' (FTY-720) is one of the strongest competitors to Biogen Idec's MS franchise** due to its potency and convenience of once daily oral dosing.



**Figure 5.6: Competitive dynamics of leading players in the autoimmune market, 2007**

"Roche (\$1.7bn) and Astellas (\$1.6bn), two of the leading companies in the global autoimmune market, also registered a strong year-on-year sales growth of 13.2% and 19.3% in 2007, driven mainly by the strong sales growth of CellCept and Prograf, respectively..."

## Use this report to...

- Assess patient potential, treatment trends and sales patterns** of major autoimmune indications over the period 2009-13, with this report's coverage of osteoarthritis, rheumatoid arthritis, crohn's disease, systemic lupus erythematosus, ulcerative colitis and multiple sclerosis markets across **Japan, France, Germany, Italy, Spain, the UK** and **the US**.
- Discover the market dynamics of the autoimmune area and understand the impact of recent events** by assessing key market trends, growth drivers and the latest issues affecting product development.
- Compare the market performance and strategic positioning** of major pharma companies' autoimmune portfolios with this report's evaluation of the franchises and market shares of **Amgen, Abbott, J&J, Pfizer, Novartis, Wyeth, Roche** and **Astellas**.
- Evaluate the autoimmune pipeline compounds of leading companies** with this report's detailed analysis of clinically differentiated pipeline products by indication, and sales forecasts for key R&D pipeline products to 2013.

## Explore issues including...



### Reduced commercial opportunity for Coxibs.

The commercial opportunity for the COX-II inhibitor class has been substantially reduced due to cardiovascular safety concerns. The US withdrawals of Vioxx and Bextra, in addition to the non-approvals of Arcoxia and Prexige, are likely to restrict the growth prospects of this class in the near future.



### Impact of high value biologic treatments.

Orencia, for use in DMARD failures, has yet to significantly affect the growth of existing agents. BMS's Orencia and Roche's Actemra target rheumatoid arthritis patients refractory to anti-TNFs, a population estimated to be between 20-40% of moderate/severe RA patients.



### Cost of MS treatments.

Research has shown that the cost of being diagnosed with MS in the UK is nearly £17,000 per person. The research also found that among 2,000 people surveyed from across the UK, half stated that they had to leave work due to MS, which increased the potential cost to over £25,000 per person when lost employment productivity is added.



**Importance of arthritis disease management.** Although several novel arthritis treatments have been launched in recent years, it is possible for many patients to achieve effective disease control from the better use of existing medications.

| Brand                 | Generic     | Company       | Sales (\$m) 2007 | Growth 06-07 (%) | Market share 2007 (%) |
|-----------------------|-------------|---------------|------------------|------------------|-----------------------|
| Celebrex              | celecoxib   | Pfizer        | 2,298            | 10.2             | 81.3                  |
| Arcoxia               | etoricoxib  | Merck         | 320              | 25.6             | 11.4                  |
| Prexige               | lumiracoxib | Novartis      | 101              | 120.6            | 3.6                   |
| Dynastat              | parecoxib   | Pfizer        | 33               | 17.9             | 1.2                   |
| Tauxib                | etoricoxib  | Merck         | 16               | 1.3              | 0.6                   |
| Exxiv                 | etoricoxib  | Merck         | 15               | 0.7              | 0.6                   |
| Solexa                | celecoxib   | Pfizer        | 4                | 29.9             | 0.2                   |
| Nucoxia               | etoricoxib  | Zydus Cadilla | 3                | 13.2             | 0.1                   |
| Etrobox               | etoricoxib  | Ranbaxy       | 2                | 9.1              | 0.1                   |
| Artilog               | celecoxib   | Esteve        | 2                | 0                | 0.1                   |
| <b>Leading brands</b> |             | <b>2,798</b>  | <b>14</b>        | <b>99.1</b>      |                       |
| Others                |             |               | 26               | 7.1              | 0.9                   |
| <b>Total</b>          |             |               | <b>2,824</b>     | <b>13.9</b>      | <b>100</b>            |

**Figure 3.27: Leading coxib brands in the global autoimmune market, 2006–07**

"Sales of the leading COX-2 inhibitors accounted for 99.1% of the global COX-2 market in 2007, with a modest growth of 14.0% in sales over 2006–07. Sales of Pfizer's Celebrex (\$2.3bn) dominated the COX-2 market, with an 81.3% share in 2007..."

## Discover...


- What will be the major growth indications in the autoimmune market over 2007–13?
- Which companies were the winners and losers in this market in 2007?
- How have major launches from companies such as Amgen, Roche, Abbott and J&J performed?
- Which companies will become key players in the autoimmune market over 2007–13?
- Which products will be affected by generic competitors over the period 2007–13?
- Which pipeline products will be the growth drivers of the future?
- Which indications have the highest levels of market potential over the period 2007–13?
- What will be the competitive landscape in osteoarthritis, rheumatoid arthritis, crohn's disease, lupus, ulcerative colitis and multiple sclerosis in 2013?

## Sample Information

### Chapter 5: Competitive landscape

#### Sales focus by drug class

Novartis markets a broad range of products across a range of therapy areas and has very comprehensive coverage of drug classes when compared to other pharmaceutical companies featured in this report. The majority of Novartis' sales are derived from products falling under the immunosuppressant class of drugs with the key drug being Sandimmun (cyclosporine), which was responsible for \$831m sales in 2007. Voltaren, an NSAID accrued \$1.1bn in 2007, making it the company's top selling drug in 2007. Voltaren is marketed in different formulations ranging from oral to topical, and thus sales accrued by Voltaren contribute towards products falling under the plain NSAIDs as well as topical anti-rheumatic agents.



#### Marketed product portfolio

Novartis' autoimmune franchise registered a growth rate of 11.7% in 2006–07, representing sales of \$2.6bn in 2007. Voltaren, the company's top selling product has witnessed a strong y-o-y sales growth of 9.7% or \$1.1bn in 2007. Marketed as an oral tablet as well as a topical formulation, the oral formulation of Voltaren had witnessed a stronger sales performance in 2006, accounting for 58.2% of total product sales.

Major growth drivers Novartis' autoimmune portfolio include Myfortic, which registered a strong y-o-y sales growth of 63.3%, garnering sales of \$149m in 2007. Myfortic is indicated for the reduction of organ rejection during renal transplants. The drug has strong clinical efficacy and tolerability profiles, translating into strong market performance since its launch in 2004. Certican, a novel proliferation signal inhibitor with immunosuppressive and anti-proliferative properties is indicated for the treatment of organ rejection in transplantation, garnered sales of \$50m in 2007, representing y-o-y sales growth of 85.5%. Prexige, a COX-2 inhibitor, registered the strongest growth rate of 120.6% among all products featured in Novartis' autoimmune franchise during the 2006–07 period. (Continued...)

**Table 5.57: Novartis' autoimmune product portfolio, 2006–07**

| Brand        | Generic       | US patent expiry date | Expected Sales 2007 (\$m) | Growth 2006–07 (%) |
|--------------|---------------|-----------------------|---------------------------|--------------------|
| Voltaren     | diclofenac    | exp                   | 1,055                     | 9.7                |
| Sandimmun    | cyclosporin   | exp                   | 831                       | 2.3                |
| Myfortic     | mycophenolate | n/a                   | 149                       | 63.3               |
| Prexige      | lumiracoxib   | 2018                  | 101                       | 120.6              |
| Simulect     | basiliximab   | 2013                  | 67                        | 11.6               |
| Ketonal      | ketoprofen    | exp                   | 53                        | 20                 |
| Certican     | everolimus    | n/a                   | 50                        | 85.5               |
| Indometacin  | indomethacin  | exp                   | 47                        | 4.4                |
| –            | nabumetone    | exp                   | 44                        | 2.9                |
| –            | diclofenac    | exp                   | 34                        | -16.8              |
| Others       | –             | –                     | 160                       | 7.9                |
| <b>Total</b> |               |                       | <b>2,596</b>              | <b>11.7</b>        |

Business Insights

## Table of Contents

### CHAPTER 1: SCOPE AND METHODOLOGY

- Scope
- Methodology

### CHAPTER 2: EPIDEMIOLOGY OF AUTOIMMUNE DISEASES

- Introduction
- **Osteoarthritis**
  - Overview
  - Diagnosis, treatment and management
  - Epidemiology
  - Forecast epidemiology
- **Rheumatoid arthritis**
  - Overview
  - Diagnosis, treatment and management
  - Epidemiology
  - Forecast epidemiology
- **Crohn's disease**
  - Overview
  - Diagnosis, treatment and management
  - Epidemiology
  - Forecast epidemiology
- **Systemic lupus erythematosus**
  - Overview
  - Diagnosis, treatment and management
  - Epidemiology
  - Forecast epidemiology
- **Ulcerative colitis**
  - Overview
  - Diagnosis, treatment and management
  - Epidemiology
  - Forecast epidemiology
- **Multiple sclerosis**
  - Overview
  - Diagnosis, treatment and management
  - Epidemiology
  - Forecast epidemiology

### CHAPTER 3: GLOBAL MARKET ANALYSIS

- Summary
- Introduction
- Market analysis by country

- Trends in generics usage and licensing
- Market analysis by drug class
- Leading brands dynamics
- **Key events in the autoimmune market**
  - Enbrel growth slowing as it faces stiff competition from Humira
  - RoActemra receives positive opinion in Europe for the treatment of RA
  - NICE admits previous guidance around sequential use of anti-TNF therapies in RA is unfair
  - Study shows prohibitive cost of MS treatment
  - Mayo Clinic collaborates to advance Crohn's treatment
  - Arthritis research shows better disease management is more important than the use of drugs
  - CellCept's off-label use in lupus continues to increase
- **Immunosuppressants**
  - Competitive dynamics of immunosuppressants
  - Leading brands of immunosuppressants
  - Key brands analysis
  - Clinical developments
  - Immunosuppressants sales forecasts to 2013
- **Specific anti-rheumatic agents**
  - Competitive dynamics of specific anti-rheumatic agents
  - Leading brands of specific anti-rheumatic agents
  - Key brands analysis
  - Specific anti-rheumatic agents sales forecasts to 2013
- **Non-steroidal plain anti-rheumatics**
  - Competitive dynamics of non-steroidal plain anti-rheumatics
  - Leading brands of non-steroidal plain anti-rheumatics
  - Key brands analysis
- Non-steroidal plain anti-rheumatics sales forecasts to 2013
- **Topical anti-rheumatics**
  - Competitive dynamics of topical anti-rheumatics
  - Leading brands of topical anti-rheumatics
  - Topical anti-rheumatic sales forecasts to 2013
- **Coxibs**
  - Competitive dynamics of coxibs
  - Leading brands of coxibs
  - Key brands analysis
  - Coxibs sales forecasts to 2013
- **Non-steroidal (combinational) anti-rheumatics**
  - Competitive dynamics of non-steroidal (combinational) anti-rheumatics
  - Leading brands of non-steroidal (combinational) anti-rheumatics
  - Non-steroidal (combinational) anti-rheumatics sales forecasts to 2013
- **Anti-rheumatic corticosteroids**
  - Competitive dynamics of anti-rheumatic corticosteroids
  - Leading brands of anti-rheumatic corticosteroids
  - Anti-rheumatic corticosteroids sales forecasts to 2013
- Total autoimmune sales forecasts to 2013

### CHAPTER 4: PIPELINE ANALYSIS

- Introduction
- Key trends in R&D
  - Biologics
  - Combination drugs
- Aggressive medical therapy becoming the standard of care
- TNF inhibitors has a strong presence in autoimmune market
- Efforts to develop fully human monoclonal antibodies

## Table of Contents

- The autoimmune pipeline
- Leading drugs in development
- Profiles of key pipeline products
  - Phase III compounds
  - Licofelone (ML3000) – Merckle GmbH
  - Ocrelizumab (R-1594) – Genentech, Biogen IDEC, Chugai and Roche
  - LymphoStat-B (belimumab) – Human Genome Sciences (HGS) and GSK
  - Ofatumumab (HuMax-CD20) – Genmab and GSK
  - Fingolimod (FTY-720) – Novartis/Mitsubishi Tanabe Pharma
  - Fampridine-SR – Acorda
  - Campath (alemtuzumab) – Genzyme and Bayer Schering Pharma
  - Recently approved/marketed drugs
  - Cimzia (certolizumab pegol) – UCB
  - Golimumab (CNTO-148) – Centocor/Schering-Plough
  - Actemra (tocilizumab) – Roche/Chugai
  - Tysabri (natalizumab) – Elan/Biogen Idec
  - Mesavance (mesalamine) – Shire
- Pipeline forecasts
  - Factors affecting forecasts
  - Autoimmune pipeline forecast

### CHAPTER 5: COMPETITIVE LANDSCAPE

- Introduction
  - Sales performance of leading players
- Detailed analysis of leading autoimmune players
- **Amgen**
  - Overview
  - Sales focus by drug class
  - Marketed product portfolio
  - R&D pipeline analysis
  - Strategic and growth analysis

- Drivers of growth
- Resistors of growth
- **Abbott**
  - Overview
  - Sales focus by drug class
  - Marketed product portfolio
  - R&D pipeline analysis
  - Strategic and growth analysis
    - Drivers of growth
    - Resistors of growth
- **Johnson and Johnson**
  - Overview
  - Sales focus by drug class
  - Marketed product portfolio
  - R&D pipeline analysis
  - Strategic and growth analysis
    - Drivers of growth
    - Resistors of growth
- **Pfizer**
  - Overview
  - Sales focus by drug class
  - Marketed product portfolio
  - R&D pipeline analysis
  - Strategic and growth analysis
    - Drivers of growth
    - Resistors of growth
- **Novartis**
  - Overview
  - Sales focus by drug class
  - Marketed product portfolio
  - R&D pipeline analysis
  - Strategic and growth analysis
    - Drivers of growth
    - Resistors of growth
- **Wyeth**
  - Overview
  - Wyeth and Pfizer
  - Sales focus by drug class
  - Marketed product portfolio
  - R&D pipeline analysis
  - Strategic and growth analysis
    - Drivers of growth
    - Resistors of growth
- **Roche**
  - Overview
  - Sales focus by drug class
  - Marketed product portfolio
  - R&D pipeline analysis
  - Strategic and growth analysis
    - Drivers of growth

- Resistors of growth
- **Astellas**
  - Overview
  - Sales focus by drug class
  - Marketed product portfolio
  - R&D pipeline analysis
  - Strategic and growth analysis
    - Drivers of growth
    - Resistors of growth

### LIST OF FIGURES

- Worldwide autoimmune market share by geography, 2007
- Sales of types of autoimmune brands, 2007
- Prevailing treatment approach for arthritis (OA and RA)
- The autoimmune pipeline by indication and stage of development, 2007
- Leading recently launched products and late-stage R&D in the autoimmune disorders market, 2008
- Competitive dynamics of the leading players in the global autoimmune market, 2007
- Amgen's autoimmune sales by drug class, 2007
- Abbott's autoimmune sales by drug class, 2007
- J&J's autoimmune sales by drug class, 2007
- Pfizer's autoimmune sales by drug class, 2007
- Novartis' autoimmune sales by drug class, 2007
- Wyeth's autoimmune sales by drug class, 2007
- Roche's autoimmune sales by drug class, 2007
- Astellas autoimmune sales by drug class, 2007

### LIST OF TABLES

- Estimated prevalence of autoimmune diseases across seven major markets, 2007
  - Estimated prevalence of OA across seven major markets,

## Table of Contents

- 2007
- Forecast epidemiology of OA across seven major markets, 2007–13
- Estimated prevalence of RA across seven major markets, 2007
- Forecast epidemiology of RA across seven major markets, 2007–13
- Estimated prevalence of CD across seven major markets, 2007
- Forecast epidemiology of CD across seven major markets, 2007–13
- Estimated prevalence of lupus across seven major markets, 2007
- Forecast epidemiology of lupus across seven major markets, 2007–13
- Estimated prevalence of UC across seven major markets, 2007
- Forecast epidemiology of UC across seven major markets, 2007–13
- Estimated prevalence of MS across seven major markets, 2007
- Forecast epidemiology of MS across seven major markets, 2007–13
- Worldwide autoimmune sales by countries, 2007
- Breakdown of the global autoimmune market by drug class, 2007
- Leading brands in the global autoimmune market, 2007
- Leading immunosuppressant brands in the global autoimmune market, 2006–07
- Remicade launch status in major markets
- Immunosuppressants sales forecast, 2007–13
- Leading specific anti-rheumatic brands in the global autoimmune market, 2006–07
- Enbrel launch status in major markets
- Specific anti-rheumatic agents sales forecast, 2007–13
- Leading non-steroidal plain anti-rheumatic brands in the global autoimmune market, 2006–07
- Non-steroidal plain anti-rheumatics sales forecast, 2007–13
- Leading topical anti-rheumatic brands in the global autoimmune market, 2006–07
- Topical anti-rheumatic sales forecast, 2007–13
- Leading coxib brands in the global autoimmune market, 2006–07
- Coxibs sales forecast, 2007–13
- Leading non-steroidal (combinational) anti-rheumatic brands in the global autoimmune market, 2006–07
- Non-steroidal (combinational) anti-rheumatics sales forecast, 2007–13
- Leading anti-rheumatic corticosteroid brands in the global autoimmune market, 2006–07
- Anti-rheumatic corticosteroids sales forecast, 2007–13
- Therapeutic sales forecasts by drug class, 2007–13
- An overview of Licofelone
- An overview of Ocrelizumab
- An overview of LymphoStat-B
- An overview of Ofatumumab
- An overview of FTY-720
- An overview of Fampridine-SR
- Fampridine-SR Phase III data
- An overview of Campath
- An overview of Cimzia
- An overview of Golimumab
- An overview of Actemra
- An overview of Tysabri
- An overview of Mesavance
- Autoimmune pipeline sales forecasts, 2007–13
- Leading players in the global autoimmune market, 2007–13 (\$m)
- Amgen's autoimmune product portfolio, 2006–07
- Amgen's autoimmune R&D product pipeline, 2008
- Abbott's autoimmune product portfolio, 2006–07
- Abbott's autoimmune R&D product pipeline, 2008
- J&J's autoimmune product portfolio, 2006–07
- J&J's autoimmune R&D product pipeline, 2008
- Pfizer's autoimmune product portfolio, 2006–07
- Pfizer's autoimmune R&D product pipeline, 2008
- Novartis' autoimmune product portfolio, 2006–07
- Novartis' autoimmune R&D product pipeline, 2008
- Wyeth's autoimmune product portfolio, 2006–07
- Wyeth's autoimmune R&D product pipeline, 2008
- Roche's autoimmune product portfolio, 2006–07
- Roche's autoimmune R&D product pipeline, 2008
- Astellas's autoimmune product portfolio, 2006–07
- Astellas's autoimmune R&D product pipeline, 2008